CD44 and neoplasm: ,18,22 We evaluated the proportion of tumour cells bound by IR700-conjugated anti-CD44 monoclonal antibody (CD44-IR700) following conventional intravenous administration and subsequently investigated whether direct intratumoural administration of CD44-IR700 enhances both the binding rate to tumour cells and the cytotoxic effect of PIT in vivo.